Pro-Pharmaceuticals, Inc., (Amex: PRW), a company “Advancing Drugs Through Glycoscience®,” is engaged in the discovery, development, and commercialization of first-in-class, therapeutic compounds for advanced treatment of cancer, liver, microbial, and inflammatory diseases. The Company’s initial focus is the development of a new generation of anti-cancer treatments using carbohydrate polymers to target deliver chemotherapeutics to reduce toxicity and increase efficacy. DAVANAT®, the Company’s lead pipeline candidate, is currently in Phase II trials for first-line treatment of colorectal and biliary cancer.

The Company’s technology is also being used to: rescue drugs that were shelved for toxicity or half-life issues; increase the solubility of existing drugs; and as new chemical entities to treat diseases such as liver and kidney fibrosis. The Company has entered into a research collaboration with the Mount Sinai School of Medicine to study the anti-fibrotic effects of the Company’s novel carbohydrate compounds on liver fibrosis, and with Brigham and Women’s Hospital to evaluate the anti-fibrotic effects of these compounds to treat acute and chronic kidney disease. The Company’s first-in-class, novel carbohydrate compounds significantly reduced collagen expression and reversed fibrosis in animal models. Whereas previously, in vitro data indicated a reversal of fibrosis markers, in this proof-of-concept animal study, the compounds clearly reduced collagen expression and reversed liver fibrosis.